8-K: Genprex Faces Nasdaq Delisting Risk After Failing to Meet Minimum Bid Price

Genprex, Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing, adding to existing concerns about stockholders' equity.

Summary

• Genprex, Inc. received a notification from Nasdaq on February 7, 2025, stating that it does not meet the minimum bid price requirement of $1.00 per share for continued listing.
• This is because the company's common stock price has been below $1.00 for the last 30 consecutive business days.
• Genprex has an initial period until August 6, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
• If compliance is not achieved by August 6, 2025, Genprex may be eligible for an additional 180-day compliance period if it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
• If Genprex fails to regain compliance or is ineligible for an extension, Nasdaq may issue a delisting notice, which the company can appeal.
• The company also received an extension to regain compliance with the minimum stockholders' equity requirement, needing to report $2.5 million in stockholders' equity in its Form 10-Q for the quarter ending March 31, 2025, and affirm its belief in maintaining compliance.
• Failure to meet this equity requirement by May 15, 2025, could also lead to delisting.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting risk and non-compliance with Nasdaq requirements. While there are opportunities to regain compliance, the uncertainty and potential for delisting weigh heavily.

Positives

• Genprex has been granted an initial compliance period until August 6, 2025, to regain compliance with the minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period if certain conditions are met.
• Nasdaq granted an extension for Genprex to regain compliance with the minimum stockholders' equity requirement.

Negatives

• Genprex is currently not in compliance with Nasdaq's minimum bid price requirement.
• The company is also not in compliance with the minimum stockholders' equity requirement.
• Failure to regain compliance with either requirement could result in delisting from The Nasdaq Capital Market.

Risks

• There is no assurance that Genprex will regain compliance with the minimum bid price requirement during the compliance period.
• There is no guarantee that the company will secure a second compliance period or maintain compliance with other Nasdaq continued listing requirements.
• Failure to meet the stockholders' equity requirement by May 15, 2025, could lead to delisting.
• An appeal against a delisting determination may not be successful.

Future Outlook

Genprex intends to monitor its stock price and assess potential actions, including a possible reverse stock split, to regain compliance with Nasdaq listing requirements, but there is no guarantee of success.

Management Comments

• The Company intends to monitor the closing bid price of its Common Stock and will assess potential actions to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Delisting notices are not uncommon for companies facing financial difficulties or market downturns, and companies often explore options like reverse stock splits or capital raising to regain compliance.

Comparison to Industry Standards

• Many biotech companies, especially those in the clinical stage, face challenges in maintaining stock prices above $1.00, particularly if clinical trial results are delayed or disappointing.
• Companies like Geron Corporation have faced similar delisting warnings in the past and have implemented reverse stock splits to regain compliance.
• The $2.5 million stockholders' equity requirement is relatively low, suggesting Genprex is a small-cap company facing significant financial hurdles.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the stock price.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's ability to raise capital and fund operations could be affected.

Next Steps

• Genprex will monitor the closing bid price of its common stock.
• Genprex will assess potential actions to regain compliance with the Minimum Bid Price Requirement.
• Genprex must report $2.5 million in stockholders' equity in its Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2025.

Key Dates

Keywords

Delisting, Minimum Bid Price, Stockholders Equity, Nasdaq, Compliance, Genprex, GNPX